Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

NCT03188965 is registered in ClinicalTrials.gov with Bayer as lead sponsor.

NCT NCT03188965
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03188965 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, First-in-human, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Maximum Tolerated Dose and / or Recommended Phase II Dose of the ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas
Lead sponsor
Bayer
Phase
Phase 1
Overall status
Completed
Start date
July 6, 2017
Completion date
September 13, 2023
Enrollment
229 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, mantle cell lymphoma, non-hodgkin's lymphoma